Announcement on Resolutions of the 16th Meeting of the 10th Board of Directors
Securities code: 600750 Securities abbreviation: China Resources Jiangzhong Announcement number: 2026-030
China Resources Jiangzhong Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 16th Meeting of the 10th Board of Directors
The company's board of directors and all directors guarantee that there are no false records, misleading statements or major omissions in this announcement, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
The 16th meeting of the 10th Board of Directors of China Resources Jiangzhong Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") was held on August 20, 2026 in the company's conference room on-site and via video. The meeting notice was issued in writing on August 10, 2026. 11 directors were expected to attend the meeting, and 11 actually attended. Some senior managers of the company attended. This meeting was convened in compliance with the relevant provisions of the Company Law and the Articles of Association.
The meeting was chaired by Mr. Liu Weiquan, chairman of the company. After full study and discussion by the directors present, the following proposals were reviewed and approved:
1. Full text and summary of the company’s 2026 semi-annual report
Voting results: 11 votes in favor, 0 votes against, 0 abstentions, passing this motion.
The board of directors believes that the full text and summary of the "China Resources Jiangzhong 2026 Semi-Annual Report" truly reflect the company's financial status and operating results for the first half of 2026. The preparation process complies with relevant laws and regulations, the relevant regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content of the report is true, accurate and complete, and there are no false records, misleading statements or major omissions.
The sixth meeting of the company's audit committee in 2026 has reviewed and approved this proposal in advance and agreed to submit it to the board of directors for review.
For details of the report, please visit the website of Shanghai Stock Exchange (www.sse.com.cn).
2. The company’s 2026 semi-annual profit distribution plan
Voting results: 11 votes in favor, 0 votes against, 0 abstentions, passing this motion.
In accordance with the relevant provisions of the Articles of Association and the authorization of the company's 2025 annual shareholders' meeting, the board of directors agreed that the company's 2026 semi-annual profit distribution plan is: based on the company's total share capital on the equity registration date of this dividend payment, a cash dividend of 5 yuan (including tax) will be distributed for every 10 shares to shareholders registered on the equity registration date of this dividend payment.
If calculated based on the company's total share capital of 635,588,289 shares as of the announcement date, 5 yuan (including tax) will be distributed for every 10 shares, with a total distribution of 317.7941 million yuan, accounting for 64.67% of the net profit attributable to the owners of the parent company in the 2026 semi-annual consolidated statement.
Before the equity registration date for the implementation of equity distribution, if the company's total share capital changes due to equity incentive shares/convertible bond conversion/share repurchase, etc., the company intends to maintain the distribution amount per share unchanged and adjust the total distribution amount accordingly.
The sixth meeting of the company's audit committee in 2026 has reviewed and approved this proposal in advance and agreed to submit it to the board of directors for review.
For details, please refer to the company's "Announcement on the Profit Distribution Plan for the Half-Year 2026" (2026-031).
3. Proposal on the 2026 performance contract for the company’s management members
Voting results: 10 votes in favor, 0 votes against, 0 abstentions, 1 avoidance vote, this motion was passed.
In order to further implement the performance management requirements of management members, reflect the guiding role of performance appraisal, and stimulate the entrepreneurial enthusiasm of cadres and officers, the company formulated the annual performance contract for management members in 2026 in accordance with the "Performance Management Measures for Managers" and the business scope of the management members.
Related director Xu Yongqian completed the avoidance voting procedure on this proposal.
The fifth meeting of the company's remuneration and assessment committee in 2026 has reviewed and approved this proposal in advance and agreed to submit it to the board of directors for review.
4. Proposal on adjusting the company’s internal audit project plan for 2026
Voting results: 11 votes in favor, 0 votes against, 0 abstentions, passing this motion.
In conjunction with the internal audit resource allocation arrangements, the board of directors agreed to change the internal audit project plan for 2026. The sixth meeting of the company's audit committee in 2026 has reviewed and approved this proposal in advance and agreed to submit it to the board of directors for review.
Announcement is hereby made.
Board of Directors of China Resources Jiangzhong Pharmaceutical Co., Ltd.
August 22, 2026